Abstract
Exogenous blood factor products, such as recombinant or human-derived factor VIIa, factor VIII, factor IX, and von Willebrand factor, are crucial for treating various bleeding disorders, but come with high risks and costs. Effective formulary management and development of institutional evidence-based guidelines for blood factor products are essential to maximize patient outcomes and minimize adverse events through an interprofessional approach. This article details the steps and considerations involved for the development of a blood factor product formulary and management at an academic medical center.
